These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32285259)

  • 1. Effectiveness of ustekinumab in patients with psoriatic arthritis in a real-world, multicenter study.
    Azuaga AB; Frade-Sosa B; Laiz A; Estrada P; Prior-Español A; Horcada L; Polino L; Moreno M; Moragues C; Urruticoechea-Arana A; Sellas A; Tandaipan JL; Torrente-Segarra V; Garcia-Miguel J; Ros I; Ordoñez S; Moya P; Reina D; Mateo-Soria L; Fito C; Beltrán E; Pujol M; Cuervo AM; Cañete JD; Ramírez J;
    Clin Rheumatol; 2020 Oct; 39(10):2963-2971. PubMed ID: 32285259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study.
    Napolitano M; Costa L; Caso F; Megna M; Scarpa R; Balato N; Ayala F; Balato A
    Clin Rheumatol; 2017 Jul; 36(7):1589-1593. PubMed ID: 28567556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study.
    Chimenti MS; Ortolan A; Lorenzin M; Triggianese P; Talamonti M; Costa L; Caso F; Favero M; Teoli M; Galluzzo M; Scarpa R; Punzi L; Perricone R; Ramonda R
    Clin Rheumatol; 2018 Feb; 37(2):397-405. PubMed ID: 29302829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry.
    Rahman P; Arendse R; Khraishi M; Sholter D; Sheriff M; Rampakakis E; Lehman AJ; Nantel F
    BMJ Open; 2020 Aug; 10(8):e036245. PubMed ID: 32792436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New onset or transition of disease state of psoriatic arthritis during treatment with ustekinumab: A single-center retrospective study.
    Asahina A; Umezawa Y; Momose M; Honda H; Yanaba K; Nakagawa H
    J Dermatol; 2017 Dec; 44(12):1380-1384. PubMed ID: 28771778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE).
    Iannone F; Santo L; Bucci R; Semeraro A; Carlino G; Paoletti F; Quarta L; Leucci P; Zuccaro C; Marsico A; Scioscia C; D'Onofrio F; Mazzotta D; Muratore M; Cantatore FP; Lapadula G
    Clin Rheumatol; 2018 Mar; 37(3):667-675. PubMed ID: 29411182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal Disease Activity and Patient-Acceptable Symptom State in Psoriatic Arthritis: A Real-World Evidence Study With Ustekinumab.
    Queiro R; Brandy A; Rosado MC; Lorenzo A; Coto P; Carriles C; Alperi M; Ballina J
    J Clin Rheumatol; 2018 Oct; 24(7):381-384. PubMed ID: 29509560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study.
    Araujo EG; Englbrecht M; Hoepken S; Finzel S; Kampylafka E; Kleyer A; Bayat S; Schoenau V; Hueber A; Rech J; Schett G
    Semin Arthritis Rheum; 2019 Feb; 48(4):632-637. PubMed ID: 30037432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison.
    Letarouilly JG; Flachaire B; Labadie C; Kyheng M; Cohen N; Sellam J; Richette P; Dieude P; Claudepierre P; Fautrel B; Houvenagel E; Nguyen CD; Guyot MH; Segaud N; Marguerie L; Deprez X; Salmon JH; Baudens G; Miceli-Richard C; Gervais E; Chary-Valckenaere I; Lafforgue P; Philippe P; Loeuille D; Richez C; Tubach F; Pham T; Flipo RM
    Rheumatology (Oxford); 2021 Jun; 60(6):2773-2782. PubMed ID: 33232465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ustekinumab in psoriatic arthritis: need for studies from real-world evidence.
    Queiro R; Coto-Segura P
    Expert Opin Biol Ther; 2018 Sep; 18(9):931-935. PubMed ID: 30044656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2.
    McInnes IB; Chakravarty SD; Apaolaza I; Kafka S; Hsia EC; You Y; Kavanaugh A
    RMD Open; 2019; 5(2):e000990. PubMed ID: 31565242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of psoriatic arthritis and comorbidities on ustekinumab outcomes in psoriasis: a retrospective, observational BADBIR cohort study.
    Tillett W; Ogdie A; Passey A; Gorecki P
    RMD Open; 2023 Jan; 9(1):. PubMed ID: 36650006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab.
    Cauza E; Spak M; Cauza K; Hanusch-Enserer U; Dunky A; Wagner E
    Rheumatol Int; 2002 Nov; 22(6):227-32. PubMed ID: 12426660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of adalimumab versus ustekinumab in the treatment of severe chronic plaque psoriasis: The results based on data from the program "treatment of moderate and severe forms of plaque psoriasis (B.47)" of the National Health Fund in Poland.
    Owczarek W; Nowakowska A; Walecka I; Ciechanowicz P; Reich A; Lesiak A; Borkowska E; Śliwczyński A; Narbutt J
    Dermatol Ther; 2022 Jun; 35(6):e15481. PubMed ID: 35363386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ustekinumab : targeting the IL-17 pathway to improve outcomes in psoriatic arthritis.
    Weitz JE; Ritchlin CT
    Expert Opin Biol Ther; 2014 Apr; 14(4):515-26. PubMed ID: 24555741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study.
    Del Alcázar E; Ferran M; López-Ferrer A; Notario J; Vidal D; Riera J; Aparicio G; Gallardo F; Vilarrasa E; Alsina M; Puig L; Ferrándiz C; Carrascosa JM
    J Dermatolog Treat; 2020 May; 31(3):222-226. PubMed ID: 30883242
    [No Abstract]   [Full Text] [Related]  

  • 18. Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study.
    Gossec L; Siebert S; Bergmans P; de Vlam K; Gremese E; Joven-Ibáñez B; Korotaeva TV; Lavie F; Noël W; Nurmohamed MT; Sfikakis PP; Sharaf M; Theander E; Smolen JS
    Arthritis Res Ther; 2023 Jun; 25(1):109. PubMed ID: 37353788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real-world multicentre Italian study.
    Dattola A; Balato A; Megna M; Gisondi P; Girolomoni G; De Simone C; Caldarola G; Cama E; Piaserico S; Fargnoli MC; Fidanza R; Parodi A; Burlando M; Offidani A; Diotallevi F; Potenza C; Conti A; Chiricozzi A; Campione E; Bianchi L
    J Eur Acad Dermatol Venereol; 2020 Dec; 34(12):2839-2845. PubMed ID: 32401377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population.
    Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
    J Dermatolog Treat; 2022 Jun; 33(4):2270-2277. PubMed ID: 34264149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.